Venetoclax is a selective inhibitor of BCL2 approved for treating chronic lymphocytic leukemia (CLL), a BCL2-dependent malignancy of differentiated B-cells [293]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.